Development of a nanoherbaceutical containing natural L-DOPA from mucuna pruriens for the prevention and treatment of Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced animal model
Objective: To prepare and evaluate the nanoherbaceutical formulation containing natural L-DOPA from Mucuna pruriens against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson's disease (PD). Background: PD is…A computational model of iron transport between the blood circulation and the brain
Objective: To create a mechanistic computational model of iron transport between the circulation and brain, permitting in silico investigation of homeostatic regulation of iron at…Does distance walked after two minutes predict total 6 minute walk test distance in people with Parkinson’s disease?
Objective: To determine if the distance walked in the first two minutes of the 6 Minute Walk Test (6MWT) accurately predicts the total distance walked…Swallowing difficulties in patients with Parkinson’s disease and Parkinsonian syndromes
Objective: To analyze the frequency and severity of swallowing difficulties in patients with Parkinson's disease (PD) and Parkinsonian syndromes. Background: Swallowing difficulties are common in…Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients
Objective: To determine whether levodopa-carbidopa intestinal gel (LCIG) infusion is able to improve freezing of gait (FOG) in advanced Parkinson's disease (PD) patients. Background: FOG…Healthcare burden of Parkinson’s disease
Objective: Evaluate healthcare costs for a cross-section of patients with Parkinson's disease (PD). Background: PD is a progressive, nonfatal condition with an increasing societal cost…Rasagiline treatment for sleep disorders in Parkinson’s disease (RaSPar) – Double-blinded, randomized, placebo-controlled, placebo run-in-phase, polysomnography clinical trial
Objective: To study the effects of Rasagiline on sleep disturbances measured by polysomnographic (PSG) evaluation of sleep efficacy and secondary measures as other sleep variables,…Sensor-based motor state detection in Parkinson’s disease to approach personalized therapy delivery
Objective: As primary objective, we acquire a data pool of medically-treated PD patients with motor fluctuations to determine the sensitivity and specificity of algorithms capable…Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…“Two odd targets” strategy in deep brain stimulation for Parkinson’s disease with unilateral dystonia
Objective: To describe a patient underwent deep brain stimulation (DBS) with different target in left and right. Background: DBS is a therapeutic option for movement…
- « Previous Page
- 1
- …
- 361
- 362
- 363
- 364
- 365
- …
- 388
- Next Page »